ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
January 25 2022 - 6:32AM
Business Wire
Researchers publish
new clinical data on NR supplementation, marking the 18th clinical
trial on ChromaDex’s Niagen® ingredient
ChromaDex Corp. (NASDAQ:CDXC) today announced results of the
18th clinical trial on its flagship Niagen® (patented nicotinamide
riboside, or “NR”) ingredient with promising, peer-reviewed
findings reported in the Journal of Clinical Investigation. The
study investigated the anti-inflammatory effects of ChromaDex’s
proprietary NR ingredient in monocytes (a type of white blood cell)
extracted from two groups: young, healthy subjects and patients
diagnosed with systemic lupus erythematosus (SLE). The study was
conducted as part of the ChromaDex External Research Program
(CERP™) and adds to a growing body of clinical evidence supporting
the potential anti-inflammatory effects of NR supplementation.
Results showed that increasing NAD+ levels through NR
supplementation reduced Type-I interferon (IFN) signaling (which
plays an important role in the human immune response) in human
monocytes both in vivo in a young, healthy population and ex vivo
in monocytes extracted from control subjects and SLE patients.
“This study supplies a mechanistic foundation as to how NR
blunts monocyte immunity and supports the need for future studies
in patients with monocyte-driven inflammatory disease,” said study
lead Michael N. Sack, M.D., Ph.D., a senior investigator in the
Laboratory of Mitochondrial Biology and Metabolism at the National
Heart, Lung, and Blood Institute at the National Institutes of
Health (NIH).
This randomized, double-blinded, placebo-controlled pilot study
featured 35 healthy volunteers (average age of 24 and average BMI
of 24 kg/m2) that were supplemented with 1000mg NR or placebo for 7
days. Extracted white blood cells from these young, healthy
subjects as well as from middle-aged lupus patients and matched
controls were then exposed to an inflammation inducer to assess
NR’s anti-inflammatory effects.
“The results from this pilot study showing an immunomodulatory
effect of NR through decreased IFN levels are promising; however,
more research is needed to understand the implications of NR
supplementation for patients with autoimmune disorders like lupus,”
said Dr. Andrew Shao, Senior Vice President of Global Regulatory
& Scientific Affairs at ChromaDex. “We look forward to
furthering this important research.”
“As the type I IFN pathway has been linked to the development
and severity of SLE, these findings support that targeting
metabolic pathways in immune cells may be beneficial in targeting
immune dysregulation in lupus cells,” said author Dr. Mariana
Kaplan, chief of the Systemic Autoimmunity branch at the NIH’s
National Institute of Arthritis and Musculoskeletal and Skin
Diseases.
This study is supported by grants from the National Heart, Lung,
and Blood Institute’s Division of Intramural Research and the
National Institute of Arthritis and Musculoskeletal and Skin
Diseases’ Division of Intramural Research, both part of NIH.
Since 2013, CERP™ has accumulated more than 240 collaborative
agreements representing $85 million in total research investment.
The program has also resulted in numerous patent applications and
licenses. Additionally, through CERP™ to date, Niagen® has been a
part of more than 65 publications, including 18 peer-reviewed,
clinical trial publications.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex: ChromaDex Corp. is a global bioscience
company dedicated to healthy aging. The ChromaDex team, which
includes world-renowned scientists, is pioneering research on
nicotinamide adenine dinucleotide (NAD+), levels of which decline
with age. ChromaDex is the innovator behind NAD+ precursor
nicotinamide riboside (NR), commercialized as the flagship
ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors
are protected by ChromaDex’s patent portfolio. ChromaDex maintains
a website at www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the Company.
Forward-Looking Statements: This release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended, including
statements related to results of the NIAGEN® studies, their
significance and whether the studies show potential for benefits on
human health. Statements that are not a description of historical
facts constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220125005438/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of Finance and Investor Relations
949-419-0288 ext. 127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024